Interstitial pneumonitis in autoimmune mice and its treatment with cyclosporin A

Okudaira, Hirokazu; Ogita, Tadaatsu; Miyamoto, Tomofumi; Shiga, Junji; Suko, Matsunobu; Okudaira, Kunio; Terada, Eiji; Ghoda, Akira; Terada, Kyoko; Saito, Muneo; Nomura, Tatsuji

doi:10.1016/0090-1229(86)90121-2

Cited by 13 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding correlates with our finding that titers of both ANA and anti-DNA antibodies decreased independently of the amount of total IgG. However, even in experimental mice, conflicting findings have been presented regarding whether CSA actually reduces titers of anti-DNA antibodies in vivo (15)(16)(17)(18)(19)(20)(21)(22). As is the case with the effects of CSA on B cells, there is little information available about the effects of the drug on the complement system.…”

Section: Discussionsupporting

confidence: 81%

Effect of low‐dose cyclosporin a on systemic lupus erythematosus disease activity

Tokuda

Kurata

Mizoguchi

et al. 1994

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To determine the effect of low‐dose cyclosporin A (CSA) treatment on disease activity in systemic lupus erythematosus (SLE). Methods. All patients in the study had active disease as defined by at least the presence of a low CH50 level. Patients were initially given 3 mg/kg/day of CSA. Dosages were adjusted individually at every visit, according to both clinical and laboratory data. Results. Eleven women with SLE were enrolled in the study; 10 were evaluable. After 20 weeks of CSA treatment, the mean score for disease activity on the SLE Disease Activity Index decreased significantly, from 10.6 to 3.8 (P = 0.02). The titer of antinuclear antibodies decreased in 8 patients and the level of anti‐DNA antibodies decreased in 5. Side effects included hypertension (40%), hypertrichosis (30%), gingival hypertrophy (10%), and a rise in the blood urea nitrogen level. Serum creatinine levels remained unchanged. Conclusion. The favorable responses observed in our patients strongly suggest that low‐dose CSA can reduce the disease activity of SLE.

show abstract

Section: Discussionsupporting

confidence: 81%

Effect of low‐dose cyclosporin a on systemic lupus erythematosus disease activity

Tokuda

Kurata

Mizoguchi

et al. 1994

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…The inhibition of the disease process is more profound than that achieved by classical photopheresis (unpublished observation) and is comparable to that of other fbrms of anti T-cell treatment [13,[27][28][29]. In addition, there is no need for this treatment to induce systemically toxic agents.…”

Section: Discussionsupporting

confidence: 63%

The Treatment of Autoimmune Disease in (NZB/NZW)F1 Mice with Syngeneic Photomodulated Splenocytes

Lin¹,

Wang²

1994

Scand J Immunol

View full text Add to dashboard Cite

(NZB x NZW)F1 (B/W) mice spontaneously develop a disease which is remarkably similar to systemic lupus erythematosus (SLE) in humans. This disease is characterized by the appearance of autoantibodies to double-stranded (ds)DNA and the subsequent development of fatal glomerulonephritis. The prophylactic treatment of B/W mice with syngeneic photomodulated autoimmune spleen cells was found to significantly improve survival, and to inhibit the outgrowth of autoreactive B cells and the production of high-titre IgG anti-dsDNA antibodies. The function of the autoreactive T cells in vivo, however, did not change significantly. Our findings suggested a novel treatment for spontaneously occurring autoantibody-related autoimmune diseases.

show abstract

“…In vitro FK506 inhibits the mixed lymphocytic reaction and the production of T-cell-derived soluble mediators, such as IL-2, IL-3 and interferon-y, and by suppressing the expression of IL-2 receptors [6,7]. In vivo, FK506 suppresses allograft rejec tion in small and large animal transplant models [10,11], graft-versus-host reactions, delayed hypersensitivity, and antibody production [12], Recent studies [3][4][5] have shown that CyA was effective in preventing the pathological changes of glomerulonephri tis and lowered the level of BUN in MRL/1 mice. There are some differences in immunosuppressive effects between CyA and FK506.…”

Section: Discussionmentioning

confidence: 99%

Effect of a Novel Immunosuppressant, FK506, on Spontaneous Lupus Nephritis in MRL/MpJ-lpr/lpr Mice

Entani

Izumino

Iida

et al. 1993

Nephron

View full text Add to dashboard Cite

We evaluated the effect of the novel immunosuppressive agent, FK506, which is known to inhibit T cell immunity, on the development of lupus nephritis in MRL/MpJ-lpr/lpr (MRL/l) mice. FK506 was administered subcutaneously (1 mg/kg body weight) from 12 to 20 weeks of age in 13 MRL/l mice with spontaneous lupus nephritis. Nine animals receiving no treatment were used as the control. FK506 significantly reduced the development of proteinuria, lowered the level of BUN, and suppressed the elevation of serum anti-dsDNA antibodies. Histopathological study showed that FK506 significantly inhibited the progression of glomerular hypercellularity and crescent formation. Glomerular deposition of C3 was significantly reduced in the FK506-treated mice compared to the nontreated controls. These findings suggest that FK506 may protect against progression of lupus nephritis in MRL/1 mice, an animal model of systemic lupus erythematosus.

show abstract

Interstitial pneumonitis in autoimmune mice and its treatment with cyclosporin A

Cited by 13 publications

References 9 publications

Effect of low‐dose cyclosporin a on systemic lupus erythematosus disease activity

Effect of low‐dose cyclosporin a on systemic lupus erythematosus disease activity

The Treatment of Autoimmune Disease in (NZB/NZW)F1 Mice with Syngeneic Photomodulated Splenocytes

Effect of a Novel Immunosuppressant, FK506, on Spontaneous Lupus Nephritis in MRL/MpJ-lpr/lpr Mice

Contact Info

Product

Resources

About